Titre : | Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers (2006) |
Titre traduit : | (Developpement et validation d'une "échelle sur l'attractivité des opiacés" : une nouvelle mesure de l'attractivité des produits opiacés chez les abuseurs potentiels.) |
Auteurs : | S. F. BUTLER ; C. BENOIT ; BUDMAN S. H. ; K. C. FERNANDEZ ; C. McCORMICK ; S. WING VENUTI ; N. KATZ |
Type de document : | Article : Périodique |
Dans : | Harm Reduction Journal (Vol.3, n°5, 2006) |
Article en page(s) : | 1-11 |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés OPIACES ; PSYCHOMETRIE ; ECHELLE D'EVALUATION ; BESOIN ; MEDICAMENTS ; ABUS ; METHODE ; TEST ; VALIDITEThésaurus géographique ETATS-UNIS |
Résumé : | Background: The growing trends in opioid abuse, assessment of the abuse liability of prescription opioid products, and growing efforts by the pharmaceutical industry to develop 'abuse-resistant' formulations highlight a need to understand the features that make one product more 'attractive' than another to potential abusers. We developed a scale to measure the 'attractiveness' of prescription opioids to potential abusers, and used the scale to measure the relative attractiveness of 14 opioid analgesic products. Methods: First, the concept of attractiveness was empirically defined with a group of prescription opioid abusers and experts in opioid abuse using a process called Concept Mapping. Abuse liability consisted of two components: factors intrinsic to the drug formulation (e.g., speed of onset, duration) and factors extrinsic to drug formulation (e.g., availability, availability of alternatives, cost). A 17-item Opioid Attractiveness Scale (OAS) was constructed, focusing on factors intrinsic to the drug product. Results: A total of 144 individuals participated in tests of validity and reliability. Internal consistency was excellent (Cronbach's alpha = 0.85-0.94). Drug rankings based on OAS scores achieved good inter-rater agreement (Kendall's W 0.37, p |
Domaine : | Autres substances / Other substances |
Refs biblio. : | 23 |
Affiliation : | Pain and Opioid Div., Inflexxion, Inc., Newton, MA, USA |
Numéro Toxibase : | 1301490 |
Centre Emetteur : | 13 OFDT |
Lien : | http://dx.doi.org/10.1186%2F1477-7517-3-5 |
Accueil